

Using Fiasp® in the under 5's: a case study

**Elmarie van Wyk
Paediatric Diabetes Dietitian
September 2022**

Background

- ✓ Diagnosed @ 18months
- ✓ Levemir & Novorapid
- ✓ Breastfeeding
- ✓ Challenging social background

Bolus habits

- Anxiety
- Injecting during/after
- Mismatch of carbs and Insulin

The x-axis and target range are the same as on the Ambulatory Glucose Profile graph above.

Ambulatory Glucose Profile

- ✓ Dexcom G6
- +/- Optimising ratio's
- +/- Optimising diet - GI
- +/- Optimising bolus behaviour
- ✗ Bolus with night time breastfeeding
- ✗ split dose Levemir
- ✗ Pump / HCL (0.5U increments)
- ✓ Fiasp®

- Selective Eater
- small appetite
- Unpredictable eating

| | Previous 3 months |
|--------------------|-------------------|
| TIR % | 35.9 |
| >10 mmol/L | 59.6 |
| >13.9 mmol/L | 36.1 |
| <3 mmol/L | 1.8 |
| <3.9 mmol/L | 4.5 |
| HbA1C mmol/L | 77 |
| CV % | 44.3 |
| SD mmol/L | 5.3 |
| ave glucose mmol/L | 12 |

Breastfeeding
20:00-02:00

Fiasp®: Fasting acting Insulin Aspart

Novorapid + 2 additional ingredients

- = speed of absorption (onset is up to 5min earlier)
- = greater early glucose-lowering effects

▪ Indication:


- Pump/MDI needing tight control
- Rapid post-meal BG rises
 - High GI foods / Breakfast spike

▪ Flexible dosing options

- At first bite (0-2min)
- Within 20min during meal if uncertain about meal acceptance


▪ Evidence Fiasp vs Novorapid:

- Improving post-prandial Glycaemia (injecting before/during/post)
- Similar Hba1C
- ?Risk of Hypos




Has it made a difference?

Clinical outcome:



- HbA1C 77 to 64mmol/L
- QOL consideration
 - ✓ Less anxiety
 - ✓ Mealtimes more enjoyable



Conclude

Fiasp® useful addition in our toolbox especially for our patients on MDI

Thank you

Any Questions?

References:

- Fath, M et all. Pediatric Diabetes. 2017;18:903-910. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
- Biester, T; Kordonouri O, Danne, T. Therapeutic advances in Endocrinology and Metabolism. 2018 vol 9(5):157-199. Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?
- European Medicine Agency: assessment report for paediatric studies submitted according to Article 46 of regulation (EC) no 1901/2006. November 2018
- European Medicine Agency: Fiasp: An overview of Fiasp and why it is authorised in the EU, 2019